Boston Scientific (NYSE:BSX) is up 1% premarket on light volume on the heels of its announcement that the FDA has approved its Eluvia Drug-Eluting Vascular Stent System that it developed specifically to treat peripheral artery disease.
The device uses a drug-polymer combination to provided sustained release of paclitaxel over a one-year period to prevent tissue regrowth that could block the stented artery.
Previously: Boston Scientific's Eluvia DES beats Cook's Zilver PTX in head-to-head study (Sept. 23)
Now read: New opinions from EMA advisor CHMP »
Subscribe for full text news in your inbox